Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultrasound therapy plus mFOLFIRINOX vs mFOLFIRINOX alone in unresectable pancreatic cancer
ChiCTR2400090269Phase 3Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of mFOLFIRINOX in pancreatic cancer (PC) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: overall survival and safety profile. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
mFOLFIRINOX
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2400090269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090269.